series-c-plus
Stage
2015
Founded
2
Investors
About
Ncardia (formerly Pluriomics) develops fully functional human cell-based assay systems for drug discovery and development. The company uses proprietary stem-cell differentiation methods to produce high-performance cell types—such as Pluricyte cardiomyocytes—used in phenotypic assays for pharmaceutical research.
Explore Ncardia's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.